Introduction
============

Gliomas are a very diverse group of brain tumors that are most commonly primary tumor and difficult to cure in central nervous system ([@ref-29]; [@ref-33]). They are classified according to their clinical and histopathological characteristics in four grades, including low-grade gliomas--(1) grade I astrocytomas---pilocytic astrocytomas, (2) grade II diffuse astrocytomas, and (3) grade II oligodendrogliomas; High-grade gliomas--(1) Grade III anaplastic astrocytomas, (2) Grade III anaplastic oligodendrogliomas, and (3) grade IV glioblastomas multiforme (GBM) ([@ref-40]). Low-grade gliomas (LGG) (astrocytomas, oligodendrogliomas, and oligoastrocytomas) are considered relatively benign, well-differentiated tumors and have 5-year survival rates of 59.9% ([@ref-7]). GBM is the most common primary malignant brain tumor in adults ([@ref-36]). Despite multiple therapeutic strategies, including surgery, radiation, and chemotherapy, the average survival time of GBM patients is less than 15 months ([@ref-28]). Additionally, approximately 70% of LGG patients develop GBM within 5--10 years ([@ref-14]). With the development of molecular pathology in gliomas, several biomarkers are routinely applied to evaluate gliomas including O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, EGFR alterations, Isocitrate dehydrogenase 1 (IDH1) or Isocitrate dehydrogenase 2 (IDH2) mutations, and 1p19q co-deletion as many of these markers have become standard of care for molecular testing and prerequisites for clinical trial enrollment ([@ref-38]). Therefore, it's necessary to differentiate LGG to GBM by understanding the molecular basis of different grades of glioma, which is an important step in defining new biomarkers and therapeutic strategies.

Gene expression profiling analysis is a useful method with broad clinical application for identifying tumor-related genes in various types of cancer, from molecular diagnosis to pathological classification, from therapeutic evaluation to prognosis prediction, and from drug sensitivity to neoplasm recurrence ([@ref-9]; [@ref-13]; [@ref-20]; [@ref-24]). In recent years, large scales of gene profiling have been made to identify the overwhelming number of genes by the use of microarrays in clinical practice, and complicated and systemic statistical analyses should be made to allow both repeatability and independent validation ([@ref-5]).

In this analysis, GEO2R online tool was applied to look for the differentially expressed genes (DEGs) according to [GSE52009](GSE52009) from GEO. Afterwards, we produced a heatmap and picked out 15 genes with higher degree of connectivity from the DEGs selected. Thereafter, we analyzed the cellular component (CC), biological process (BP), molecular function (MF), and Kyoto Encyclopedia of Gene and Genome (KEGG) pathways of the DEGs. In addition, the overall survival (OS) analysis and expression of these hub genes were made online. Then, we established protein--protein interaction (PPI) network of the DEGs and managed a gene set enrichment analysis (GSEA) using GBM patient gene profiling data ([GSE53733](GSE53733)).

Materials and Methods
=====================

Data of microarray
------------------

Gene expression profile of [GSE52009](GSE52009), [GSE53733](GSE53733), and [GSE4290](GSE4290) were downloaded from GEO database, which is a public and freely accessible database. Based on Agilent GPL6480 platform (Agilent-014850 Whole Human Genome Microarray 4x44K G4112F), [GSE52009](GSE52009) dataset included 120 samples, containing 60 WHO II samples and 24 WHO IV samples. [GSE53733](GSE53733) was based on the GPL570 platform ((HG-U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array), which contained 70 GBM samples. [GSE4290](GSE4290) was based on the GPL570 platform ((HG-U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array), which included 180 samples, containing 76 WHO II samples and 81 WHO IV samples.

Screen genes of differential expression
---------------------------------------

Differentially expressed genes between low-grade glioma and high-grade glioma was detected by GEO2R, which was an online analysis tool based on R language ([@ref-8]). We set the adjust *P*-value \< 0.05 and \|logFC\| ≥ 2 as the selection criteria to decrease the false positive rate and false discovery rate. Furthermore, the top 15 genes with higher degree of connectivity were selected as hub genes among the 133 discovered DEGs which includes 56 downregulated genes and 77 upregulated genes. In addition, we used visual hierarchical cluster analysis to show the two groups by Morpheus online analysis software (<https://software.broadinstitute.org/morpheus/>) and volcano plot of two groups by ImageGP (<http://www.ehbio.com/ImageGP/index.php/Home/Index/index.html>) after the relative raw data of TXT files were downloaded.

Gene ontology and KEGG pathway analysis of DEGs
-----------------------------------------------

With functions including MF, biological pathways, and CC, gene ontology (GO) analysis we annotated genes and gene products ([@ref-15]). KEGG comprises a set of genome and enzymatic approaches and abiological chemical energy online database ([@ref-19]). It is a resource for systematic analysis of gene function and related high-level genome functional information. Database for annotation, visualization and integrated discovery (DAVID) (<https://david.ncifcrf.gov/>) can provide systematic and comprehensive biological function annotation information for high-throughput gene expression ([@ref-11]). Therefore, we applied GO and KEGG pathway analyses to the DEGs by using DAVID online tools at functional level. We considered *P* \< 0.05 had significant differences. In addition, we used visual analysis to show GO Enrichment plot of two groups by ImageGP (<http://www.ehbio.com/ImageGP/index.php/Home/Index/index.html>) after the relative raw data of TXT files were downloaded ([@ref-16]).

PPI network and module analysis
-------------------------------

The online tool, search tool for the retrieval of interacting genes (STRING), is designed to demonstrate the interaction between different proteins ([@ref-42]). STRING in Cytoscape was applied and mapped the DEGs into STRING to detect the possible relationship among the selected DEGs. We set the confidence score ≥0.4, maximum number of interactors = 0 as the selection criteria. In addition, the molecular complex detection (MCODE) was used to screen modules of PPI network in Cytoscape with degree cutoff = 2, node score cutoff = 0.2, *k*-core = 2, and max. depth = 100. DAVID was used to perform the signal pathway analysis of genes in the module. A total of 15 hub genes were also mapped into STRING with confidence score ≥0.4, maximum number of interactors ≤5. The potential information was explored through GO and KEGG pathway analysis.

Comparing the expression level of the hub genes
-----------------------------------------------

GlioVis (<http://gliovis.bioinfo.cnio.es/>) is a user-friendly web application for data visualization and analysis to explore brain tumors expression datasets, which was used to analyze the gene expression data of brain tumors and normal samples based on the TCGA datasets. ([@ref-3]). The customizable functions are provided such as analyzing the differences of expression levels between glioblastoma and low-grade glioma, so the expression of these genes was demonstrated. And the relationship could be visualized through the boxplot. All values are presented as the mean ± SD. All statistical analyses were performed by SPSS 19.0 software. A difference of *P* \< 0.05 was considered statistically significant.

Gene expression profile and gene set enrichment analysis
--------------------------------------------------------

The expression profiles of [GSE53733](GSE53733) were downloaded from the GEO data base. We used GSEA (<http://www.broadinstitute.org/gsea>) to detect the potential genes influenced by Serum amyloid A1 (SAA1) and tissue inhibitor of metalloproteinases-1 (TIMP1) through Java programming. According to their hub genes expression level (top 50%: high vs. bottom 50%: low), we divided the patients into two groups, and GSEA was conducted to analyze the effects of selected genes expression level on different BP. We set *P*-value of \<0.05 and false discovery rates of \<0.25 as selection criteria to confirm significant gene sets.

Human tissue samples
--------------------

Low-grade gliomas and GBM tissues were collected from the Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China. The clinical glioma specimens were examined and diagnosed by pathologists at Renmin Hospital of Wuhan University. This study was approved by the Institutional Ethics Committee of the Faculty of Medicine at Renmin Hospital of Wuhan University (approval number: 2012LKSZ (010) H). Informed consent was obtained from all patients whose tissues were used.

RNA extraction and quantitative real-time PCR
---------------------------------------------

Total RNA from cancer tissues was prepared using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and cDNA was synthesized using a PrimeScript RT Reagent Kit with gDNA Eraser (RR047A; Takara, Kusatsu, Japan). Quantitative real-time PCR (qPCR) for SAA1 and TIMP1 mRNA levels were performed using SYBR Premix Ex Taq II (RR820A, Takara, Kusatsu, Japan) according to the manufacturer's instructions and performed in Bio-Rad CFX Manager 2.1 real-time PCR Systems (Bio-Rad, Hercules, CA, USA). GAPDH was used as internal controls. The data were analyzed by the relative Ct method and expressed as a fold change compared with the control. The primer sequences included the following: GAPDH 5′-GGAGCGAGATCCCTCCAAAAT-3′(Forward), 5′-GGCTGTTGTCATACTTCTCATGG-3′(Reverse); SAA1 5′-CCTGGGCTGCAGAAGTGATCAGCGA-3′(Forward), 5′-AGTCCTCCGCACCATGGCCAAAGAA-3′(Reverse); TIMP1 5′-CTTCTGCAATTCCGACCTCGT-3′(Forward), 5′-ACGCTGGTATAAGGTGGTCTG-3′(Reverse).

Results
=======

Identification of DEGs and hub genes
------------------------------------

A total of 60 WHO II samples and 24 WHO IV samples from [GSE52009](GSE52009) were selected in this study. DEGs were detected by applying the GEO2R online analysis tool, setting adjust *P*-value \< 0.05 and \|logFC\| ≥ 2 as selection criteria. A total of 133 differential expressed genes, containing 77 upregulated genes and 56 downregulated genes, were detected after the analysis of [GSE52009](GSE52009). In addition, we selected 15 hub genes with higher degree of connectivity ([Table 1](#table-1){ref-type="table"}). The results were validated with a DEG expression heatmap and volcano plot of the all downregulated genes and upregulated genes ([Fig. 1](#fig-1){ref-type="fig"}).
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###### Top 15 hub genes with higher degree of connectivity.

![](peerj-07-6560-g006)

  Gene     Degree   *P*-value
  -------- -------- -----------
  VEGFA    13       7.55E-07
  NDC80    8        7.16E-09
  IL8      8        5.15E-07
  CENPA    7        3.31E-09
  CENPF    7        6.06E-10
  NCAPG    7        9.09E-10
  ASPM     7        1.86E-08
  RRM2     7        1.13E-09
  ITGA2    6        2.45E-09
  ANXA1    6        6.32E-08
  CDCA2    6        6.42E-09
  PLAT     5        2.64E-08
  PARPBP   5        6.34E-15
  TIMP1    4        2.06E-06
  SAA1     4        2.40E-06

![Differentially expressed gene expression heatmap and volcano plot of glioma.\
(A) Differentially expressed gene expression heatmap of glioma (all upregulated and downregulated genes). (B) Differentially expressed genes were selected by volcano plot filtering (fold change ≥ 1 and *P*-value ≤ 0.05). The blue point in the plot represents the differentially expressed genes with statistical significance.](peerj-07-6560-g001){#fig-1}

GO function and KEGG pathway enrichment analysis
------------------------------------------------

To explore more particular knowledge of the selected DEGs, we used DAVID to gain the results of GO function and KEGG pathway enrichment analysis. All DEGs were imported to DAVID software, and GO analysis results demonstrated that upregulated and downregulated DEGs were particularly enriched in the following biological processes (BP): cell migration, locomotion and leukocyte migration, cell motility for upregulated DEGs, and for downregulated DEGs nervous system development, brain development and regulation of cell projection organization ([Table 2](#table-2){ref-type="table"}; [Figs. 2A](#fig-2){ref-type="fig"} and [2B](#fig-2){ref-type="fig"}). The upregulated DEGs were enriched in phospholipase A2 inhibitor activity, growth factor binding, extracellular matrix (ECM) structural construction, receptor binding, and the downregulated DEGs were enriched in calcium ion binding, structural construction of myelin sheath, and protein complex binding for MF ([Table 2](#table-2){ref-type="table"}; [Fig. 2](#fig-2){ref-type="fig"}). Moreover, GO CC analysis showed that the upregulated DEGs were enriched in the proteinaceous ECM, ECM and cytoplasmic membrane-bounded vesicle lumen, and downregulated DEGs enriched in neuron part, myelin sheath, and internode region of axon ([Table 2](#table-2){ref-type="table"}; [Figs. 2A](#fig-2){ref-type="fig"} and [2B](#fig-2){ref-type="fig"}).
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###### Gene ontology analysis of differentially expressed genes associated with LGG and HGG.

![](peerj-07-6560-g007)

  Expression      Category                                                   Term                                      Count      \%         *P*-value   FDR
  --------------- ---------------------------------------------------------- ----------------------------------------- ---------- ---------- ----------- ----------
  Upregulated     GOTERM_BP_FAT                                              GO:0016477---cell migration               13         22.80702   3.95E-05    0.067618
  GOTERM_BP_FAT   GO:0050900---leukocyte migration                           8                                         14.03509   5.28E-05   0.090452    
  GOTERM_BP_FAT   GO:0040011---locomotion                                    14                                        24.5614    1.09E-04   0.185762    
  GOTERM_BP_FAT   GO:0051674---localization of cell                          13                                        22.80702   1.22E-04   0.208673    
  GOTERM_BP_FAT   GO:0048870---cell motility                                 13                                        22.80702   1.22E-04   0.208673    
  GOTERM_MF_FAT   GO:0019838---growth factor binding                         4                                         7.017544   0.004366   5.428929    
  GOTERM_MF_FAT   GO:0019834---phospholipase A2 inhibitor activity           2                                         3.508772   0.010298   12.37092    
  GOTERM_MF_FAT   GO:0005102---receptor binding                              10                                        17.54386   0.010815   12.95228    
  GOTERM_MF_FAT   GO:0005201---extracellular matrix structural constituent   3                                         5.263158   0.018986   21.69308    
  GOTERM_MF_FAT   GO:0005125---cytokine activity                             4                                         7.017544   0.019477   22.19193    
  GOTERM_CC_FAT   GO:0005615---extracellular space                           16                                        28.07018   3.09E-06   0.003877    
  GOTERM_CC_FAT   GO:0005578---proteinaceous extracellular matrix            7                                         12.2807    4.24E-04   0.531176    
  GOTERM_CC_FAT   GO:0031012---extracellular matrix                          8                                         14.03509   5.41E-04   0.676623    
  GOTERM_CC_FAT   GO:0060205---cytoplasmic membrane-bounded vesicle lumen    4                                         7.017544   0.002985   3.680925    
  GOTERM_CC_FAT   GO:0031983---vesicle lumen                                 4                                         7.017544   0.003066   3.779192    
  Downregulated   GOTERM_BP_FAT                                              GO:0007399---nervous system development   15         31.91489   3.29E-04    0.533895
  GOTERM_BP_FAT   GO:0007420---brain development                             7                                         14.89362   0.00548    8.553316    
  GOTERM_BP_FAT   GO:0060322---head development                              7                                         14.89362   0.007003   10.80691    
  GOTERM_BP_FAT   GO:0031344---regulation of cell projection organization    6                                         12.76596   0.011466   17.11031    
  GOTERM_BP_FAT   GO:0007417---central nervous system development            7                                         14.89362   0.019918   27.91963    
  GOTERM_MF_FAT   GO:0005509---calcium ion binding                           6                                         12.76596   0.021579   24.70502    
  GOTERM_MF_FAT   GO:0019911---structural constituent of myelin sheath       2                                         4.255319   0.02239    25.5132     
  GOTERM_MF_FAT   GO:0032403---protein complex binding                       5                                         10.6383    0.092825   71.83703    
  GOTERM_CC_FAT   GO:0097458---neuron part                                   15                                        31.91489   6.61E-06   0.007993    
  GOTERM_CC_FAT   GO:0045202---synapse                                       9                                         19.14894   8.96E-04   1.078808    
  GOTERM_CC_FAT   GO:0043005---neuron projection                             9                                         19.14894   0.00424    5.011629    
  GOTERM_CC_FAT   GO:0033269---internode region of axon                      2                                         4.255319   0.01097    12.49482    
  GOTERM_CC_FAT   GO:0043209---myelin sheath                                 4                                         8.510638   0.01206    13.65505    

![GO analysis results of DEGs.\
(A) and downregulated DEGs (B) were particularly enriched in BP, MF, and CC. (C) The most significantly enriched KEGG pathway of the upregulated DEGs. GO, gene ontology; BP, biological process; MF, molecular function; CC, cell component; KEGG, Kyoto Encyclopedia of Genes and Genomes.](peerj-07-6560-g002){#fig-2}

Interestingly, the most significantly enriched of KEGG pathway only showed in upregulated pathway, including adhesion, ECM-receptor interaction, amoebiasis, and PI3K-Akt signaling pathway ([Table 3](#table-3){ref-type="table"}; [Fig. 2C](#fig-2){ref-type="fig"}).
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###### KEGG pathway analysis of differentially expressed genes associated with HGG.

![](peerj-07-6560-g008)

  Expression     Category                              Term                      Count      \%         *P*-value                     Genes                         FDR
  -------------- ------------------------------------- ------------------------- ---------- ---------- ----------------------------- ----------------------------- ----------
  Upregulated    KEGG_PATHWAY                          hsa04510:Focal adhesion   4          7.017544   0.007454                      LAMB1, VEGFA, ITGA2, COL1A1   7.094772
  KEGG_PATHWAY   hsa04512:ECM-receptor interaction     3                         5.263158   0.012926   LAMB1, ITGA2, COL1A1          12.01164                      
  KEGG_PATHWAY   hsa05146:Amoebiasis                   3                         5.263158   0.018811   LAMB1, CXCL8, COL1A1          17.03775                      
  KEGG_PATHWAY   hsa04151:PI3K-Akt signaling pathway   4                         7.017544   0.02979    LAMB1, VEGFA, ITGA2, COL1A1   25.72978                      
  KEGG_PATHWAY   hsa05200:Pathways in cancer           4                         7.017544   0.041599   LAMB1, VEGFA, ITGA2, CXCL8    34.15806                      

Hub genes and module screening from PPI network
-----------------------------------------------

Protein--protein interaction network of the top 15 hub genes with higher degree of connectivity was made based on the information in the STRING protein query from public databases ([Fig. 3A](#fig-3){ref-type="fig"}). The top module was selected by using MCODE plug-in in the PPI network ([Fig. 3B](#fig-3){ref-type="fig"}).

![protein--protein interaction network and top module of hub genes.\
(A) The protein--protein interaction network of the top 15 hub genes. (B) Top module from the protein--protein interaction network.](peerj-07-6560-g003){#fig-3}

The Kaplan--Meier plotter of hub genes
--------------------------------------

The website, <http://gepia.cancer-pku.cn/>, freely provides the prognostic data of the hub genes. It was found that expression of VEGFA (HR 4.2, *P* \< 0.001) was associated with worse OS for glioblastoma patients, as well as NDC80 (HR 5.8, *P* \< 0.001), CENPA (HR 5.3, *P* \< 0.001), CENPF (HR 3.9, *P* \< 0.001), Non-SMC condensin I complex subunit G (NCAPG) (HR 5.6, *P* \< 0.001), ASPM (HR 5, *P* \< 0.001), ITGA2 (HR 3, *P* \< 0.001), TIMP1 (HR 7, *P* \< 0.001)and SAA1 (HR 4.8, *P* \< 0.001) ([Fig. 4](#fig-4){ref-type="fig"}).

![Prognostic value of hub genes in glioma patients.\
Prognostic value of hub genes (VEGFA, NDC80, CENPA, CENPF, NCAPG, ASPM, ITGA2, TIMP1, and SAA1) in glioma patients. HR, hazard ratio. (A) VEGFA (HR 4.2, *P* \< 0.001) was associated with worse OS for glioblastoma patients; (B) NDC80 (HR 5.8, *P* \< 0.001) was associated with worse OS for glioblastoma patients; (C) CENPA (HR 5.3, *P* \< 0.001) was associated with worse OS for glioblastoma patients; (D) CENPF (HR 3.9, *P* \< 0.001) was associated with worse OS for glioblastoma patients; (E) NCAPG (HR 5.6, *P* \< 0.001) was associated with worse OS for glioblastoma patients; (F) ASPM (HR 5, *P* \< 0.001) was associated with worse OS for glioblastoma patients; (G) ITGA2 (HR 3, *P* \< 0.001) was associated with worse OS for glioblastoma patients; (H) TIMP1 (HR 7, *P* \< 0.001) was associated with worse OS for glioblastoma patients; (I) SAA1 (HR 4.8, *P* \< 0.001) was associated with worse OS for glioblastoma patients.](peerj-07-6560-g004){#fig-4}

Expression level and relationship with molecular pathologic diagnosis of hub genes
----------------------------------------------------------------------------------

We used data from GlioVis to detect the hub gene expression level between GBM and LGG including astrocytoma, oligodendroglioma, and oligoastrocytoma, the expression level of SAA1 and TIMP1 significantly increased in GBM ([Figs. 5A](#fig-5){ref-type="fig"} and [5C](#fig-5){ref-type="fig"}). The expression levels of SAA1 have no significant difference in three kind of LGG ([Fig. 5B](#fig-5){ref-type="fig"}). However, the expression level of TIMP1 is significantly higher in astrocytoma than oligodendroglioma and oligoastrocytoma ([Fig. 5D](#fig-5){ref-type="fig"}). We further verified our finding in the [GSE4290](GSE4290) dataset and got consistent result ([Fig. S1](#supp-1){ref-type="supplementary-material"}). Then we detected the sample collected in our hospital and found both SAA1 and TIMP1 are significantly increased in GBMs compared with LGG ([Fig. S2](#supp-2){ref-type="supplementary-material"}; [Table S1](#supp-3){ref-type="supplementary-material"}). We also detect the relationship between expression level and molecular pathologic diagnosis of hub genes. We found both SAA1 and TIMP1 increase in both Isocitrate dehydrogenase (IDH) mutant IDH wild type. The same results were found in MGMT promoter and non-deletion of chromosome 1p.19q. Because of the limited samples in the datasets, we didn't the result of co-deletion of chromosome 1p.19q. ([Figs. 5E](#fig-5){ref-type="fig"} and [5F](#fig-5){ref-type="fig"}) Further, we also found that both SAA1 and TIMP1 played important roles in MES-like in the Isocitrate dehydrogenase (IDH) wild type ([Figs. 5G](#fig-5){ref-type="fig"} and [5H](#fig-5){ref-type="fig"}).

![The expression level and potential function of SAA1 and TIMP1.\
(A) SAA1 significantly increased in glioblastomas; (B) The expression level of SAA1 have no significant difference in LGG; (C) TIMP1 significantly increased in glioblastomas; (D) TIMP1 is significantly higher in astrocytoma than oligodendroglioma and oligoastrocytoma; (E) and (F) SAA1 and TIMP1 increase in both IDH mutant and IDH wild type. The same results were found in MGMT promoter and non-deletion of chromosome 1p.19q; (G) and (H) SAA1 and TIMP1 played important roles in MES-like in the IDH wild type; (I) and (J) SAA1 regulates biology process associated with inflammatory response processes and cytokine mediated signaling pathway; (K) and (L) TIMP1 negatively regulates adaptive immune response based on somatic recombination of immune receptors built from a leucine-rich superfamily and TIMP1 also negatively regulates response to interferons.](peerj-07-6560-g005){#fig-5}

Gene expression profile and gene set enrichment analysis
--------------------------------------------------------

We managed a GSEA by using GBM patient gene profiling data ([GSE53733](GSE53733)), and showed in [Fig. 5](#fig-5){ref-type="fig"}, gene set differences in SAA1 in low versus high glioma patients indicated that SAA1 regulates biology process mainly associated with inflammatory response processes (*P* \< 0.001 FDR = 0.012) and cytokine mediated signaling pathway (*P* \< 0.001 FDR = 0.012) ([Figs. 5I](#fig-5){ref-type="fig"} and [5J](#fig-5){ref-type="fig"}). We considered that SAA1 may negatively regulate inflammatory response and might promote the survival of cancer cells. We concluded that TIMP1 might negatively regulates adaptive immune response based on somatic recombination of immune receptors built from a leucine-rich superfamily (*P* \< 0.001 FDR = 0.021) and response to interferon (*P* \< 0.001 FDR = 0.027) may promote the survival of cancer cells ([Figs. 5K](#fig-5){ref-type="fig"} and [5L](#fig-5){ref-type="fig"}).

Discussion
==========

In this study, we identified 15 DEGs between GBM and LGG and used a series of bioinformatics analyses to screen the key genes and pathways associated with glioma. [GSE52009](GSE52009) dataset contains 60 WHO II samples and 24 WHO IV samples. In order to improve the statistical power of DEGs, we defined that the absolute value of the logarithm (base 2) fold change (logFC) greater than 2 and 133 DEGs were obtained. Bioinformatics analysis on DEGs, including GO enrichment, KEGG pathway, PPI network, and survival analysis, expression level, gene set enrichment analysis, found GBM genes and pathways that play important roles in glioma development.

The GO analysis showed that the upregulated DEGs were mainly associated with cell migration, ECM structural construction, cell motility and downregulated DEGs were involved central nervous system development, calcium ion binding and internode region of axon. Additionally, the KEGG pathways of upregulated DEGs regulate focal adhesion, ECM-receptor interaction, PI3K-Akt signaling pathway. Among these DEGs, we selected 15 hub genes with higher degree of connectivity. In addition, we found several hub genes with worse OS and higher expression level in glioma patients, including VEGFA, NDC80, TIMP1, SAA1, CENPA, CENPF, and NCAPG and we firstly found relationship of SAA1, TIMP1, and molecular pathology in GBM. We could hypothesize that these genes might contribute to the malignance of glioma and SAA1 and TIMP-1 may be biomarkers in GBM.

Glioblastomas multiformes are highly vascularized cancers with high levels of VEGF and VEGF-A seems to be the most critical one, mainly operating in the activation of quiescent endothelial cells and promoting cell migration and proliferation ([@ref-34]). NDC80 is a mitotic regulator and a major element of outer kinetochore which has been reported to drive functions in assembly checkpoint and chromosome segregation of mitosis regulation. NDC80 was mainly enriched in proliferation and procession of cancer in previous studies ([@ref-41]). Addition, a recently study demonstrated that the expression of NDC80 in HEB was significantly lower than in GBM cell lines and had a negative correlation with the prognosis of patients ([@ref-45]). Interleukin (IL)-8 is a chemokine which was upregulated by NF-κB in GBMs and promotes a more aggressive phenotype mostly through the enhancement of angiogenesis and cell migration. More and more evidence demonstrated that the IL-8 molecular pathways will allow the generation of both novel therapeutic approaches and diagnostic tools ([@ref-23]). NCAPG8 is a novel mitotic gene for cell proliferation and migration, which has been less well studied in cancers, and a recently study demonstrated that NCAPG over expressed in GBMs and promote cell proliferation ([@ref-25]).

Serum amyloid A1 which was secreted by liver is an acute-phase high density lipo-protein in immune response. Injury, inflammation, and brain trauma can elevate the plasma levels of SAA1 ([@ref-30]; [@ref-43]). Further, it has long been suspected that SAA1 might be a prognostic marker and predictor of cancer risk. Elevated levels of SAA1 in the serum of cancer patients directly correlate with poor prognosis and tumor aggressiveness in various types of cancer, including lung cancer ([@ref-6]), cell renal carcinoma ([@ref-22]), melanomas ([@ref-12]) and so on. Normal brain does not express SAA1 ([@ref-26]), though an in vitro study demonstrated that microglia and astrocytes are responsive to SAA ([@ref-44]). Recently, it has been reported that SAA1 the expression levels in GBM patients are upregulated on both mRNA and protein in human GBMs, and SAA1 involves in angiogenesis via HIF-1α and tumor associated macrophages. Serum levels of SAA1 were associated with the grades of gliomas but did not affect the clinical outcomes of patients with GBM ([@ref-21]). Consistently, SAA1 has been reported as a molecular/metabolic signature that can help identify patients are at high risk of malignant GBM and promotes glioma cells migration and invasion through integrin aVb3 ([@ref-27]). Further, although it's unknown why SAA1 upregulated in GBM and other malignant cancers, it has been speculated that SAA proteins play a primary role in the regulation of immunity and invasion processes ([@ref-32]), which is consistent with the result of our study. Thus, we hypothesis SAA1 could be a biomarker of GBM and predict the prognosis of GBM patients. The mechanism of SAA1 regulate in GBM need further research.

The tissue inhibitors of metalloproteinases (TIMPs, including TIMP-1, TIMP-2, TIMP-3, TIMP-4) are well known play critical roles in both metastasis and invasion through ECM remodeling which are controlled by the activity of matrix metalloproteinases (MMPs) ([@ref-17]; [@ref-37]). Among the four well-known TIMPs characterized so far, most focus has been on TIMP-1 defined as a naturally occurring inhibitor of most MMPs, a family of zinc dependent endopeptidases essential for degrading components of the ECM ([@ref-1]). In addition, TIMP1 shows protease-independent function including anti-apoptotic, antiangiogenic, and differentiation activities in cells ([@ref-4]; [@ref-31]). Over the past year, more and more studies have focused on the influence of TIMP1 in cancers. Serum or urine levels of TIMP1 are also considered as a diagnostic predictor in pancreatic ductal carcinomas containing extensive desmoplasia ([@ref-18]; [@ref-39]). Increased levels of cytosolic TIMP1 in pretreatment tumor tissue is associated with a significantly shorter OS in patients with breast cancer receiving standard adjuvant chemotherapy ([@ref-10]). It has also been reported that low expression of TIMP-1 in glioblastoma patient predicts longer survival. The shorter survival of glioblastoma patients with a high tumor TIMP-1 level may be explained by the antiapoptotic effect of TIMP-1 preventing apoptosis induced by radiation and chemotherapy ([@ref-1]). More recently, [@ref-2] demonstrated that Co-expression of TIMP-1 and CD63 might have effects in glioblastoma stemness and may predict the poor prognosis of patients through influencing tumor aggressiveness and resistance of therapy. We consider that TIMP-1 can be identified as a future biomarker for prognosis or monitoring patients' treatment response. However, all these studies didn't demonstrate the specific mechanism, which is the direction for further researches.

Additionally, large-scale efforts aimed at characterizing the genomic alterations in human glioblastoma, however, these efforts helped to clarify the role of genomic alterations in the pathogenesis of glioblastoma but were not designed to address intratumor heterogeneity. Recently, [@ref-35] described the Ivy Glioblastoma Atlas in which we have assigned key genomic alterations and gene expression profiles to the tumor's anatomic features. The anatomic feature included the leading edge (LE), infiltrating tumor (IT), cellular tumor (CT). We also found that the expression levels of SAA1 and TIPM-1 were higher in IT and CT than LE from the atlas. However, the specific mechanisms of these differences aren\'t presently clear; therefore, we need to do further research in the future.

Conclusion
==========

We found that these key genes (identified by a series of bioinformatics analyses on DEGs between glioblastoma samples and low-grade glioma samples) were most likely related to the development of glioma. These hub genes could also affect the survival time of glioma patients. These identified genes and pathways provide a more detailed molecular mechanism for underlying glioma initiation and development. According to the study, SAA1 and TIMP1 can be considered as biomarkers or therapeutic targets for monitoring patient treatment response for glioblastoma. However, further molecular and biological experiments are required to confirm the functions of the key genes in glioblastoma.
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###### The expression of SAA1 and TIMP1 in [GSE4290](GSE4290) Dataset.

###### 

Click here for additional data file.
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###### The expression of SAA1 and TIMP1 in Human tissues.

Figure S2: (A) SAA1 significantly increased in glioblastomas; (B) TIMP1 significantly increased in glioblastomas.
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Click here for additional data file.
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###### Demographicdata from patients analyzed in this study.

*LGG*: low grade glioma; *GBM*: glioblastoma; *M*: male; *F*: female; \*Age at diagnosis was calculated from date of birth to date of surgery.

###### 

Click here for additional data file.
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